×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| POLY MEDICURE LTD. | 4251.42 | 879.29 | 3840.47 | 8.67 | 20,458 | 57.2 |
| ALEMBIC PHARMACEUTICALS LTD. | 15019.6 | 1035.2 | 14941.7 | 5.27 | 18620 | 31.4 |
| NEULAND LABORATORIES LTD. | 3006.09 | 137.08 | 2927.53 | 10.68 | 18410 | 140.0 |
Poly Medicure Ltd, with Security Code 531768, is a leading player in the Medical Equipment & Supplies industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 293.3 | 305.6 | 319.9 | 320.9 | 360.9 | 367.4 | 402.5 | 410.9 | 421.0 | 384.0 |
| Expenses | 211.6 | 220.5 | 237.3 | 236.5 | 263.5 | 266.2 | 289.5 | 295.3 | 304.9 | 282.4 |
| Operating Profit | 81.7 | 85.1 | 82.6 | 84.4 | 97.4 | 101.2 | 112.9 | 115.6 | 116.1 | 101.6 |
| OPM % | 27.85% | 27.85% | 25.82% | 26.3% | 26.99% | 27.54% | 28.06% | 28.13% | 27.57% | 26.46% |
| Other Income | 8.7 | 13.2 | 12.8 | 16.6 | 15.7 | 16.8 | 27.2 | 21.7 | 23.9 | 41.1 |
| Interest | 2.2 | 2.4 | 2.1 | 3.4 | 2.9 | 3.0 | 3.1 | 3.1 | 2.2 | 2.8 |
| Depreciation | 14.7 | 15.0 | 15.3 | 15.5 | 16.2 | 19.0 | 20.1 | 20.8 | 21.3 | 22.8 |
| Profit before tax | 73.4 | 80.9 | 78.0 | 82.1 | 94.0 | 96.1 | 116.9 | 113.4 | 116.5 | 117.1 |
| Tax % | -21.7% | -25.2% | -24.1% | -25.1% | -24.9% | -24.7% | -25.4% | -24.9% | -25.6% | 24.9% |
| Net Profit | 57.5 | 60.5 | 59.2 | 61.5 | 70.5 | 72.3 | 87.2 | 85.2 | 86.7 | 87.9 |
| EPS in Rs | 5.99 | 6.3 | 6.17 | 6.4 | 7.35 | 7.53 | 8.98 | 8.48 | 0 | 8.67 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 284.8 | 306.9 | 320.8 | 337.3 | 339.6 | 378.1 | 384.8 | 420.0 | 424.2 | 440.8 |
| Expenses | 213.8 | 223.6 | 233.6 | 253.1 | 249.4 | 281.5 | 280.9 | 304.7 | 309.7 | 321.3 |
| Operating Profit | 71.0 | 83.2 | 87.2 | 84.2 | 90.2 | 96.6 | 103.9 | 115.3 | 114.5 | 119.5 |
| OPM % | 24.93% | 27.12% | 27.18% | 24.97% | 26.57% | 25.55% | 27.01% | 27.46% | 27% | 27.11% |
| Other Income | 14.4 | 8.5 | 13.9 | 14.1 | 16.6 | 15.0 | 16.9 | 26.1 | 21.8 | 24.3 |
| Interest | 4.8 | 2.3 | 2.5 | 2.2 | 3.5 | 3.1 | 3.2 | 3.3 | 3.3 | 2.2 |
| Depreciation | 14.2 | 14.8 | 15.5 | 16.0 | 16.2 | 16.2 | 19.7 | 20.9 | 21.5 | 21.0 |
| Profit before tax | 66.4 | 74.6 | 82.3 | 80.1 | 87.1 | 92.2 | 98.0 | 117.2 | 111.5 | 120.6 |
| Tax % | -25.3% | -21.9% | -24.5% | -23.4% | -26.2% | -26.1% | -24.9% | -26% | -25.1% | -25.7% |
| Net Profit | 50.0 | 58.8 | 62.7 | 62.2 | 65.0 | 68.4 | 74.0 | 87.5 | 85.2 | 91.8 |
| EPS in Rs | 5.2 | 6.13 | 6.53 | 6.47 | 6.77 | 7.12 | 7.71 | 9.01 | 8.48 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 20% |
| 3 Years: | 22% |
| TTM: | 23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 29% |
| 3 Years: | 36% |
| TTM: | 40% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 57% |
| 3 Years: | 52% |
| 1 Year: | 35% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 19% |
| 3 Years: | 22% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 29% |
| 3 Years: | 34% |
| TTM: | 31% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 57% |
| 3 Years: | 52% |
| 1 Year: | 35% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|